Loading...

KPTI KARYOPHARM THERAPEUTICS INC US FDA Inspections 8-K Filing

KRYP

KPT

KARYOPHARM THERAPEUTICS INC

(KPTI)

2024 8-K

Show Summary

Summary

Potential Financing Transac...

Equity Offerings

Financial Statements

Financial Results

Executive Compensation

Shareholder Approvals

Management Change

Regulatory Update

Management Change

Lease Amendment

Financial Results

Clinical Trial Update

Nasdaq Compliance Notice

Annual Meeting Approval

Exchange of Convertible Sen...

Debt Restructuring, Convert...

Financial Results Announcement

Compliance Regained

Earnings Reports

Resignation of Director

Financial Results Announcement

Appointment of Independent ...

Annual Meeting Results

Financial Results Announcement

Regulation FD Disclosure

Equity Awards Approval

Earnings Report

External Links:

Karyopharm Therapeutics Inc. announced a change in the co-primary endpoint for its Phase 3 clinical trial in myelofibrosis, replacing total symptom score improvement with absolute total symptom score following FDA feedback.

AI Assistant

KARYOPHARM THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.